Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 3, 2016, Pages 432-440

  Shanavas, Mohamed ^a   Popat, Uday ^b   Michaelis, Laura C ^c   Fauble, Veena ^d   McLornan, Donal ^e   Klisovic, Rebecca ^f   Mascarenhas, John ^g   Tamari, Roni ^h   Arcasoy, Murat O ⁱ   Davies, James ^j   Gergis, Usama ^k   Ukaegbu, Oluchi C ^l   Kamble, Rammurti T ^m   Storring, John M ⁿ   Majhail, Navneet S ^o   Romee, Rizwan ^p   Verstovsek, Srdan ^b   Atenafu, Eshetu G ^a   Vasu, Sumithira ^f   Ernst, Brenda ^d   Hanif, Ahmad ^c   Champlin, Richard ^b   Hari, Paremeswaran ^c   Gupta, Vikas ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d MAYO CLINIC   (United States)

^e KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ DUKE CANCER INSTITUTE   (United States)

^j OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^m CENTER FOR CELL AND GENE THERAPY   (United States)

ⁿ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^o LERNER RESEARCH INSTITUTE   (United States)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Allogeneic transplantation; JAK1 2 inhibitors; Myelofibrosis; Ruxolitinib; Survival

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MOMELOTINIB; RUXOLITINIB; THYMOCYTE ANTIBODY; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; BLADDER DISEASE; BLEEDING; BRAIN HEMORRHAGE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL TOXOPLASMOSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CONDITIONING; CONFIDENCE INTERVAL; CYTOPENIA; DIARRHEA; DISEASE COURSE; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; INVASIVE ASPERGILLOSIS; LEG PAIN; LEUKEMIA; LISTERIOSIS; LIVER TOXICITY; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MIDDLE AGED; MORTALITY; MUCORMYCOSIS; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; MYCOBACTERIOSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMONIA; PROGNOSIS; PULMONARY CANDIDIASIS; RASH; RELAPSE; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SPLENOMEGALY; STOMATITIS; SYMPTOM; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN OCCLUSION; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING; WEIGHT REDUCTION; WHOLE BODY RADIATION; WITHDRAWAL SYNDROME; ALLOGRAFT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PRIMARY MYELOFIBROSIS; SURVIVAL RATE;

ADULT; AGED; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84950996639     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.005     Document Type: Article

References (37)

1. 1 Lundberg, P., Karow, A., Nienhold, R., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123 (2014), 2220–2228.
2. 2 Kralovics, R., Passamonti, F., Buser, A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005), 1779–1790.
3. 3 Levine, R.L., Wadleigh, M., Cools, J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005), 387–397.
4. 4 Verstovsek, S., Mesa, R.A., Gotlib, J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366 (2012), 799–807.
5. 5 Harrison, C., Kiladjian, J.-J., Al-Ali, H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (2012), 787–798.
6. 6 Ballen, K.K., Shrestha, S., Sobocinski, K.A., et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16 (2010), 358–367.
7. 7 Gupta, V., Hari, P., Hoffman, R., Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 120 (2012), 1367–1379.
8. 8 McLornan, D.P., Mead, A.J., Jackson, G., Harrison, C.N., Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 157 (2012), 413–425.
9. 9 Kröger, N., Holler, E., Kobbe, G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114 (2009), 5264–5270.
10. 10 Gupta, V., Malone, A.K., Hari, P.N., et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 20 (2014), 89–97.
11. 11 Abelsson, J., Merup, M., Birgegård, G., et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 47 (2012), 380–386.
12. 12 Rondelli, D., Goldberg, J.D., Isola, L., et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 124 (2014), 1183–1191.
13. 13 Wong, K.M., Atenafu, E.G., Kim, D., et al. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1589–1599.
14. 14 Tamari, R., Mughal, T.I., Rondelli, D., et al. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?. Bone Marrow Transplant 50 (2015), 628–636.
15. 15 Gupta, V., Gotlib, J., Radich, J.P., et al. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant 20 (2014), 1274–1281.
16. 16 Ballinger, T.J., Savani, B.N., Gupta, V., et al. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. Eur J Haematol 94 (2015), 115–119.
17. 17 Robin, M., Francois, S., Huynh, A., et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC. Blood, 122, 2013, 306 [Abstract].
18. 18 Shanavas, M., Messner, H.A., Atenafu, E.G., et al. Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant 49 (2014), 1162–1169.
19. 19 Jaekel, N., Behre, G., Behning, A., et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 49 (2014), 179–184.
20. 20 Stübig, T., Alchalby, H., Ditschkowski, M., et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 28 (2014), 1736–1738.
21. 21 Lebon, D., Rubio, M.T., Legrand, F., et al. Ruxolitinib for patients with primary or secondary myelofibrosis before allogeneic hematopoietic stem cell transplantation (allo-HSCT): a retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Blood, 122, 2013, 2111 [Abstract].
22. 22 Hanif, A., Hari, P., Atallah, E., et al. Ruxolitinib prior to allogeneic stem cell transplantation does not adversely affect post-transplant outcomes. Blood, 124, 2014, 1851 [Abstract].
23. 23 Heine, A., Held, S.A.E., Daecke, S.N., et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122 (2013), 1192–1202.
24. 24 Heine, A., Brossart, P., Wolf, D., Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. Blood 122 (2013), 3843–3844.
25. 25 Passamonti, F., Cervantes, F., Vannucchi, A.M., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115 (2010), 1703–1708.
26. 26 Sorror, M.L., Maris, M.B., Storb, R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005), 2912–2919.
27. 27 Caramazza, D., Begna, K.H., Gangat, N., et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 25 (2011), 82–88.
28. 28 Bacigalupo, A., Ballen, K., Rizzo, D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15 (2009), 1628–1633.
29. 29 Bearman, S.I., Appelbaum, F.R., Buckner, C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (1988), 1562–1568.
30. 30 Tefferi, A., Cervantes, F., Mesa, R., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122 (2013), 1395–1398.
31. 31 Tefferi, A., Pardanani, A., Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86 (2011), 1188–1191.
32. 32 Verstovsek, S., Mesa, R.A., Gotlib, J.R., et al. Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. J Clin Oncol, 30, 2012 Abstract 6624.
33. 33 Dai, T., Friedman, E.W., Barta, S.K., Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 31 (2013), e430–e432.
34. 34 Tefferi, A., Litzow, M.R., Pardanani, A., Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365 (2011), 1455–1457.
35. 35 Beauverd, Y., Samii, K., Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol 100 (2014), 498–501.
36. 36 Cervantes, F., Vannucchi, A.M., Kiladjian, J.J., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122 (2013), 4047–4053.
37. 37 Verstovsek, S., Kantarjian, H.M., Estrov, Z., et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120 (2012), 1202–1209.